EVH
Evolent Health Inc Class A
$3.90
-$0.06(-1.52%)
50
Overall
60
Value
45
Tech
47
Quality
Market Cap
$594.83M
Volume
1.97M
52W Range
$2.10 - $12.07
Target Price
$5.64
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Mar | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $434.9M | $627.1M | $846.4M | $924.6M | $215.1M | $908.0M | $1.4B | $2.0B | $2.6B | $1.9B | ||
| Total Revenue | $434.9M | $627.1M | $846.4M | $924.6M | $215.1M | $908.0M | $1.4B | $2.0B | $2.6B | $1.9B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | $696.6M | -- | $657.6M | $1.0B | $1.5B | $2.2B | $1.5B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $434.9M | $627.1M | $846.4M | $228.1M | $215.1M | $250.4M | $316.6M | $460.5M | $367.4M | $399.9M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-507.8M | $-674.5M | $1.2B | $1.2B | $-231.0M | $279.5M | $336.5M | $358.1M | $263.1M | $303.9M | ||
| Research & Development | $-17.2M | $-18.2M | $19.8M | $15.1M | -- | $15.5M | -- | -- | -- | -- | ||
| Research Expense | -- | -- | $19.8M | $15.1M | -- | $15.5M | -- | -- | -- | -- | ||
| Selling, General & Administrative | $205.7M | $235.4M | $257.0M | $210.4M | -- | $219.5M | $269.3M | $358.1M | $263.1M | $303.9M | ||
| Selling & Marketing Expenses | $205.7M | $235.4M | -- | -- | $58.6M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-10.9M | $-14.2M | $257.0M | $210.4M | $-6.1M | $219.5M | $269.3M | $358.1M | $263.1M | $303.9M | ||
| Salaries & Wages | $-20.4M | $-17.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $32.4M | $44.5M | $60.9M | $60.8M | -- | $60.0M | $67.2M | $123.4M | -- | -- | ||
| Depreciation & Amortization | $32.4M | $44.5M | $60.9M | $60.8M | $15.2M | $60.0M | $67.2M | $123.4M | -- | -- | ||
| Amortization | $-23.7M | $-29.9M | $581.4M | $19.0M | $-11.9M | $426.3M | $745.8M | $8.5M | $3.5M | $7.8M | ||
| Other Operating Expenses | $269.2M | $398.6M | $-648.3M | $-696.5M | $-231.0M | $-657.4M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-72.3M | $-51.5M | $-306.6M | $-267.6M | $215.1M | $-42.4M | $3.6M | $-71.2M | $-40.5M | $-410.1M | ||
| EBITDA | $-42.0M | $-4.2M | $-247.3M | $-240.7M | -- | $49.1M | $23.0M | $-21.0M | $83.6M | $-353.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $3.6M | $5.5M | $14.5M | $28.3M | -- | $25.4M | $15.6M | $54.2M | $24.7M | $57.5M | ||
| Intinc | $1.7M | $3.4M | $4.0M | $2.6M | -- | $407.0K | $1.4M | $5.3M | $5.5M | $4.2M | ||
| Net Non-Operating Interest Income/Expense | $-2.0M | $-2.0M | $-10.5M | $-25.7M | $-6.2M | $-25.0M | $-14.2M | $-48.9M | $-19.2M | $-53.3M | ||
| Other Income/Expense | $2.2M | $632.0K | $-4.1M | $46.4M | $10.8M | $248.0K | $-28.0M | $193.8M | $147.9M | $163.5M | ||
| Other Special Charges | $171.0K | $3.1M | $17.9M | $-4.8M | -- | $-146.0K | $-10.1M | $-21.6M | $241.0K | $-3.2M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | $-2.2M | $17.4M | $9.0M | -- | $7.3M | -- | -- | -- | -- | ||
| Special Income Charges | $4.9M | $14.6M | $-199.8M | $-215.1M | $12.1M | $-7.3M | $-27.0M | $-24.3M | $-25.6M | $-398.0M | ||
| Impairment of Capital Assets | $-4.9M | $-12.4M | $199.8M | $215.1M | -- | -- | -- | -- | -- | $398.0M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-75.2M | $-51.2M | $-317.6M | $-302.2M | $215.1M | $-29.0M | $-46.5M | $-148.2M | $-38.3M | $-477.1M | ||
| Pre-Tax Income | $-76.4M | $-54.2M | $-327.1M | $-330.5M | $215.1M | $-29.8M | $-62.1M | $-202.4M | $-63.0M | $-534.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-6.6M | $40.0K | $-21.5M | $-2.4M | -- | $483.0K | $-43.4M | $-89.4M | $-1.4M | $-100.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-60.7M | $-52.7M | $-302.0M | $-334.2M | $216.5M | $-37.6M | $-19.2M | $-113.0M | $-61.6M | $-534.5M | ||
| Net Income (Continuing Operations) | $-60.7M | $-52.7M | $-302.0M | $-334.2M | $216.5M | $-54.9M | $-18.7M | $-113.0M | $-61.6M | $-534.5M | ||
| Net Income (Discontinued Operations) | $-60.7M | $-52.7M | $-302.0M | $-334.2M | $216.5M | $-37.6M | $-19.2M | $-113.0M | $-61.6M | $-534.5M | ||
| Net Income (Common Stockholders) | $-60.7M | $-52.7M | $995.7M | $-334.2M | $216.5M | $-37.6M | $-19.2M | $-142.3M | $-93.5M | $-579.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-144.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-507.8M | $-674.5M | $1.2B | $1.2B | $-231.0M | $937.1M | $1.4B | $1.9B | $2.5B | $1.8B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $64.4M | $77.3M | $82.4M | $84.9M | -- | $86.1M | $93.7M | $111.3M | $114.7M | $114.2M | ||
| Average Shares Outstanding (Diluted) | $64.4M | $77.4M | $82.4M | -- | -- | $86.1M | $93.7M | $111.3M | $114.7M | $114.2M | ||
| Shares Outstanding | $77.4M | $82.6M | $84.7M | $86.1M | $86.9M | $90.8M | $111.1M | $115.4M | $116.6M | $111.6M | ||
| Basic EPS | $-0.94 | $-0.85 | $-3.67 | $-3.94 | $-0.12 | $-0.44 | $-0.20 | $-1.28 | $-0.81 | $-5.07 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-3.67 | $-3.94 | $-0.13 | $-0.35 | $-0.20 | $-1.28 | $-0.81 | $-5.07 | ||
| Diluted EPS | $-0.94 | $-0.68 | $-3.66 | $-3.94 | $-0.12 | $-0.44 | $-0.20 | $-1.28 | $-0.81 | $-5.07 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.66 | -- | $-0.13 | $-0.35 | $-0.20 | $-1.28 | $-0.81 | $-5.07 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | $60.7M | -- | -- | -- | -- | -- | -- | $29.2M | $31.8M | $44.9M | ||
| Allowances For Construction | -- | -- | -- | -- | -- | -- | -- | $123.4M | $118.4M | $115.9M | ||
| Basic Discontinuous Operations | -- | -- | -- | -- | $0.01 | $-0.09 | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | $0.01 | $-0.09 | -- | -- | -- | -- | ||
| Earnings from equity interest | $-1.8M | $-4.7M | $-9.5M | $10.0M | -- | $13.2M | $4.6M | $1.3M | $-3.4M | $400.0K | ||
| Earnings From Equity Interest Net Of Tax | $-1.8M | $-4.7M | $-9.5M | $10.0M | -- | $13.2M | $4.6M | $1.3M | $-3.4M | $400.0K | ||
| Gain On Sale Of P P E | -- | -- | $9.6M | $-698.0K | -- | -- | -- | $-8.1M | $-18.9M | $14.2M | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | $1.4M | $-6.8M | -- | -- | -- | -- | ||
| Interest Expense Operating | $-2.5M | $-2.5M | $-5.0M | $-13.4M | -- | $-7.1M | -- | -- | -- | -- | ||
| Minority Interests | $9.1M | $1.5M | $3.6M | $619.6M | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | $-6.1M | $1.4M | $-14.1M | $-7.3M | $-500.0K | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | $-6.1M | -- | $-7.3M | $-463.0K | -- | -- | -- | ||
| Other Gand A | $-10.9M | $-14.2M | $257.0M | $210.4M | $-6.1M | $219.5M | $269.3M | $358.1M | $263.1M | $303.9M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $47.1M | -- | -- | -- | $24.1M | $2.6M | -- | ||
| Other Write Off | -- | $70.9M | -- | $1.7M | -- | $6.1M | -- | -- | $118.4M | -- | ||
| Preferred Stock Dividends | $60.7M | -- | -- | -- | -- | -- | -- | $29.2M | $31.8M | $44.9M | ||
| Rent And Landing Fees | $-10.9M | $-14.2M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $205.7M | $235.4M | -- | -- | $58.6M | -- | -- | -- | -- | -- | ||
| Restruct | -- | $-2.2M | $17.4M | $9.0M | -- | $7.3M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EVH | $3.90 | -1.5% | 1.97M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Evolent Health Inc Class A Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW